Dam G, Gronbaek H, Sorbye H, Thiis Evensen E, Paulsson B, Sundin A, Jensen C, et al. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. Neuroendocrinology 2020;110:217-224.
Dauben L, Simon MC, Strassburger K, Burkart V, Weber KS, Schinner S, Roden M, et al. Comparison of the diagnostic accuracy of the current guidelines for detecting insulinoma. Eur J Endocrinol 2019;180:381-386.
Grubbs EG, Halperin DM, Waguespack SG, Gagel RF. History of the multiple endocrine neoplasia workshops and overview of MEN2019. Endocr Relat Cancer 2020 Jun 1;ERC-20- 0201.
Hofland J, Herrera-Martinez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer 2019;26:R145- R156.
Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev 2020;41 (2):371-403.
Mafficini A, Scarpa A. Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Rev 2019;40:506-536.
Oka N, Kasajima A, Konukiewitz B, Sakurada A, Okada Y, Kameya T, Weichert W, et al. Classification and Prognostic Stratification of Bronchopulmonary Neuroendocrine Neoplasms. Neuroendocrinology 2020;110:393-403.
Oleinikov K, Dancour A, Epshtein J, Benson A, Mazeh H, Tal I, Matalon S, et al. Endoscopic Ultrasound-Guided Radiofrequency Ablation: A New Therapeutic Approach for Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab 2019;104:2637-2647.
Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2020;31:844-860.
Sundlov A, Sjogreen-Gleisner K, Tennvall J, Dahl L, Svensson J, Akesson A, Bernhardt P, et al. Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up. Neuroendocrinology 2020. https://doi.org/10.1159/000507761
Veltroni A, Cosaro E, Spada F, Fazio N, Faggiano A, Colao A, Pusceddu S, et al. Clinico- pathological features, treatments and survival of malignant insulinomas: a multicenter study. Eur J Endocrinol 2020;182:439-446.
Vesterinen T, Leijon H, Mustonen H, Remes S, Knuuttila A, Salmenkivi K, Vainio P, et al. Somatostatin Receptor Expression Is Associated With Metastasis and Patient Outcome in Pulmonary Carcinoid Tumors. J Clin Endocrinol Metab 2019;104:2083-2093.

Alemyar, A., A.L.F. van der Kooi, and J.S.E. Laven Anti-Müllerian Hormone and Ovarian Morphology in Wome With Hypothalamic Hypogonadism. J Clin Endocrinol Metab. 2020; 105: e203645.
Amiri, M., et al. A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. Hum Reprod. 2020; 35: 175-186.
Benetti-Pinto, C.L., et al. Sleep quality and fatigue in women with premature ovarian insufficiency receiving hormone therapy: a comparative study. Menopause (New York, N.Y.). 2019; 26: 1141-1145.
Copp, T., et al. Impact of a diagnosis of polycystic ovary syndrome on diet, physical activity and contraceptive use in young women: findings from the Australian Longitudinal Study of Women's Health. Hum Reprod. 2020; 35: 394-403.
Finkelstein, J.S., et al. Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation. J Clin Endocrinol Metab. 2020; 105: e1862-71.
Fraison, E., et al. Pregnancy following diagnosis of premature ovarian insufficiency: a systematic review.Reproductive biomedicine online. 2019; 39: 467-476.
Gaspard, U., et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause. 2020; Aug;27(8):848-857.
Gazarra, L.B.C., et al. Bone mass in women with premature ovarian insufficiency: a comparative study between hormone therapy and combined oral contraceptives. Menopause. 2020. https://doi.org/10.1097/GME.0000000000001592
Honigberg, M.C., et al. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA. 2019: e1919191.
Ozdemir, K., et al. Depression, anxiety, and fear of death in postmenopausal women. Menopause. 2020; https://doi.org/10.1097/GME.0000000000001578
Persson, S., et al. Fecundity among women with polycystic ovary syndrome (PCOS)-a population-based study. Human reproduction (Oxford, England). 2019; 34: 2052-2060.
Santen, R.J., et al. Underlying Breast Cancer Risk and Menopausal Hormone Therapy. J Clin Endocrinol Metab. 2020; 105: e203645.
Trabert, B., et al. Association of Circulating Progesterone With Breast Cancer Risk Among Postmenopausal Women. JAMA Netw Open. 2020; 3: e203645.
Trower, M., et al. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause. 2020 May;27(5):498-505.
Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394: 1159-1168.
Xu, X., M. Jones, and G.D. Mishra Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum Reprod. 2020; 35: 203-211.

Ambery P, Parker VE, Stumvoll M, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391: 2607- 2618.
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID- 19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792.
Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724–32.
Bach RG, Cannon CP, Giugliano RP, et al. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019;4(9):846-54. https://doi.org/10.1001/jamacardio.2019.2306
Batty GD, Deary IJ, Hamer M, Frank P, Bann D. Association of Childhood Psychomotor Coordination With Survival Up to 6 Decades Later. JAMA Netw Open. 2020; 3: e204031 https://doi.org/10.1001/jamanetworkopen.2020.4031
Blümel, J.E., et al., Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study. Gynecological Endocrinology, 2020: p. 1-5.
Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, et al. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020 May;2(5):413–31.
Chung WK, Erion K, Florez JC, Hattersley AT, Hivert M-F, Lee CG, et al. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020 Jul;43(7):1617–35.
Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, García-Pérez L-E, Lakshmanan M, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020 Jul;19(7):582–90.
de Cabo, R. and M.P. Mattson, Effects of Intermittent Fasting on Health, Aging, and Disease. N Engl J Med, 2019. 381(26): p. 2541-2551.
Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, et al. Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Diabetes Obes Metab. 2020 Jun;22(6):938–46.
Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:458–464.
Ge L, Sadeghirad B, Ball GDC, da Costa BR, Hitchcock CL, Svendrovski A, Kiflen R, Quadri K, Kwon HY, Karamouzian M, Adams-Webber T, Ahmed W, Damanhoury S, Zeraatkar D, Nikolakopoulou A, Tsuyuki RT, Tian J, Yang K, Guyatt GH, Johnston BC. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ. 2020; 369:m696 https://doi.org/10.1136/bmj.m696
Gerstein HC, Hart R, Colhoun HM, Diaz R, Lakshmanan M, Botros FT, et al. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes Endocrinol. 2020 Feb;8(2):106–14.
Gerstein, H.C., et al., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet, 2019. 394(10193): p. 121- 130.
Giammanco A, Cefalu AB, Noto D, Averna MR. Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide. Curr Med Chem. 2020;27(23):3773-83. https://doi.org/10.2174/0929867326666190121120735
Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(3):179–88.
Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care. 2020 Jun;43(6):1352–5.
Kahl S, Gancheva S, Straßburger K, Herder C, Machann J, Katsuyama H, et al. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care. 2020 Feb;43(2):298–305.
Kelly AS, Auerbach P, Barrientos-Perez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382:2117-2128.
Kelly, A.S., et al., A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med, 2020; 382(22):2117-2128.
Koren MJ, Sabatine MS, Giugliano RP, et al. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019;74(17):2132-46. https://doi.org/10.1016/j.jacc.2019.08.1024
Laffel, L.M., et al., Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA, 2020. 323(23): p. 2388-2396.
Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworthkg, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow CM, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7:344- 355.
Luirink IK, Wiegman A, Kusters DM, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019;381(16):1547-56. https://doi.org/10.1056/NEJMoa1816454
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019. https://doi.org/10.1093/eurheartj/ehz455
ornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020 Jun;8(6):546–50.
Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, et al. Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. J Clin Endocrinol Metab. 2020 Mar 1;105(3). https://doi.org/10.1210/clinem/dgz047
Pasquali R, Casanueva F, Haluzik M, van Hulsteijn L, Ledoux S, Monteiro MP, Salvador J, Santini F, Toplak H, Dekkers OM. European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity. Eur J Endocrinol. 2020;182:G1-G32 https://doi.org/10.1530/EJE-19-0893
Pratley, R., et al., Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet, 2019. 394(10192): p. 39-50.
Pratley, R.E., et al., Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA, 2020. 323(23): p. 2397-2406.
Reaven, P.D., et al., Intensive Glucose Control in Patients with Type 2 Diabetes — 15- Year Follow-up. New England Journal of Medicine, 2019. 380(23): p. 2215-2224.
Younossi ZM, Tampi RP, Racila A, Qiu Y, Burns L, Younossi I, et al. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. Diabetes Care. 2020 Feb;43(2):283–9.
Zaharia OP, Strassburger K, Strom A, Bönhof GJ, Karusheva Y, Antoniou S, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019;7(9):684–94.
Zelniker, T.A., et al., SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta- analysis of cardiovascular outcome trials. The Lancet, 2019. 393(10166): p. 31-39.
Zhu L, She Z-G, Cheng X, Qin J-J, Zhang X-J, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020 Jun;31(6):1068-1077.e3.
Bhatt, D. L. et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N. Engl. J. Med. (2020). https://doi.org/10.1056/nejmoa2030183
Bhatt, D. L. et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N. Engl. J. Med. (2020). https://doi.org/10.1056/nejmoa2030183
Bhatt, D. L. et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N. Engl. J. Med. (2020). https://doi.org/10.1056/nejmoa2030183

Altieri B, Ronchi CL, Kroiss M, Fassnacht M 2020 Next-generation therapies for adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020 May;34(3):101434
Bancos I, Taylor AE, Chortis V, Sitch AJ, Jenkinson C, Davidge-Pitts CJ, Lang K, Tsagarakis S, Macech M, Riester A, Deutschbein T, Pupovac ID, Kienitz T, Prete A, Papathomas TG, Gilligan LC, Bancos C, Reimondo G, Haissaguerre M, Marina L, Grytaas MA, Sajwani A, Langton K, Ivison HE, Shackleton CHL, Erickson D, Asia M, Palimeri S, Kondracka A, Spyroglou A, Ronchi CL, Simunov B, Delivanis DA, Sutcliffe RP, Tsirou I, Bednarczuk T, Reincke M, Burger-Stritt S, Feelders RA, Canu L, Haak HR, Eisenhofer G, Dennedy MC, Ueland GA, Ivovic M, Tabarin A, Terzolo M, Quinkler M, Kastelan D, Fassnacht M, Beuschlein F, Ambroziak U, Vassiliadi DA, O'Reilly MW, Young WF, Jr., Biehl M, Deeks JJ, Arlt W, Investigators EE-A. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINEACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020 Jul 23;S2213-8587(20)30218-7. https://doi.org/10.1016/S2213-8587(20)30218-7
Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020; 173:10-20.
Buffet A, Ben Aim L, Leboulleux S, Drui D, Vezzosi D, Libe R, Ajzenberg C, Bernardeschi D, Cariou B, Chabolle F, Chabre O, Darrouzet V, Delemer B, Desailloud R, Goichot B, Esvant A, Offredo L, Herman P, Laboureau S, Lefebvre H, Pierre P, Raingeard I, Reznik Y, Sadoul JL, Hadoux J, Tabarin A, Tauveron I, Zenaty D, Favier J, Bertherat J, Baudin E, Amar L, Gimenez-Roqueplo AP, French Group of Endocrine T, Network C. Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. J Clin Endocrinol Metab. 2019; 104:1109-1118.
Buitenwerf E, Osinga TE, Timmers H, Lenders JWM, Feelders RA, Eekhoff EMW, Haak HR, Corssmit EPM, Bisschop P, Valk GD, GrooteVeldman R, Dullaart RPF, Links TP, Voogd MF, Wietasch G, Kerstens MN, investigators P. Efficacy of alpha-blockers on hemodynamic control during pheochromocytoma resection - a randomized controlled trial. J Clin Endocrinol Metab. 2020 Jul 1;105(7):2381-2391. https://doi.org/10.1210/clinem/dgz188
Burger-Stritt S, Eff A, Quinkler M, Kienitz T, Stamm B, Willenberg HS, Meyer G, Klein J, Reisch N, Droste M, Hahner S. Standardised patient education in adrenal insufficiency: a prospective multi-centre evaluation. Eur J Endocrinol. 2020; 183:119-127.
Carneiro BA, Konda B, Costa RB, Costa RLB, Sagar V, Gursel DB, Kirschner LS, Chae YK, Abdulkadir SA, Rademaker A, Mahalingam D, Shah MH, Giles FJ. Nivolumab in metastatic adrenocortical carcinoma: results of a phase II trial. J Clin Endocrinol Metab. 2019 Dec 1;104(12):6193-6200.
Ding J, Zhang Y, Wen J, Zhang H, Wang H, Luo Y, Pan Q, Zhu W, Wang X, Yao S, Kreissl MC, Hacker M, Tong A, Huo L, Li X. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020 Mar 23. https://doi.org/10.1007/s00259-020-04722-0
Ekstrom M, Nwaru BI, Hasvold P, Wiklund F, Telg G, Janson C. Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden. Allergy. 2019; 74:2181-2190.
Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, Prokop L, Murad MH, O'Reilly MW, Arlt W, Bancos I. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Ann Intern Med. 2019; 171:107-116.
Fassnacht M, Assie G, Baudin E, Eisenhofer G, Fouchardiere C, Haak HR, de Krijger R, Porpiglia F, Terzolo M, Berruti A Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol 2020 Aug 24:S0923-7534(20)42107-6. https://doi.org/10.1016/j.annonc.2020.08.2099
Geroula A, Deutschbein T, Langton K, Masjkur J, Pamporaki C, Peitzsch M, Fliedner S, Timmers H, Bornstein SR, Beuschlein F, Stell A, Januszewicz A, Prejbisz A, Fassnacht M, Lenders JWM, Eisenhofer G. Pheochromocytoma and paraganglioma: clinical featurebased disease probability in relation to catecholamine biochemistry and reason for disease suspicion. Eur J Endocrinol. 2019; 181:409-420.
Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019; 7:253. Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG, Capanu M, Zamarin D, Saltz LB, Ariyan CE, Untch BR, O'Reilly EM, Gopalan A, Berger MF, Olino K, Segal NH, Reidy- Lagunes DL. PD-1 Blockade in Advanced Adrenocortical Carcinoma. J Clin Oncol. 2020 Jan 1;38(1):71-80. https://doi.org/10.1200/JCO.19.01586
Jaffe G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J, Chertow GM, Leppert JT, Bhalla V. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study. Hypertension. 2020; 75:650-659.
Kahramangil B, Kose E, Remer EM, Reynolds JP, Stein R, Rini B, Siperstein A, Berber E. A Modern Assessment of Cancer Risk in Adrenal Incidentalomas: Analysis of 2219 Patients. Ann Surg. 2020 Jun 11. https://doi.org/10.1097/SLA.0000000000004048
Kawashima J, Araki E, Naruse M, Kurihara I, Takahashi K, Tamura K, Kobayashi H, Okamura S, Miyauchi S, Yamamoto K, Izawa S, Suzuki T, Tanabe A, Group JJS. Baseline Plasma Aldosterone Level and Renin Activity Allowing Omission of Confirmatory Testing in Primary Aldosteronism. J Clin Endocrinol Metab. 2020 May 1;105(5):dgaa117. https://doi.org/10.1210/clinem/dgaa117
Kitamoto T, Kitamoto KK, Omura M, Takiguchi T, Tsurutani Y, Kubo H, Yamazaki Y, Sasano H, Saito J, Nishikawa T 2020 Precise Mapping of Intra-Adrenal Aldosterone Activities Provides a Novel Surgical Strategy for Primary Aldosteronism. Hypertension. 2020 Sep;76(3):976-984. https://doi.org/10.1161/HYPERTENSIONAHA.119.14341
Laugesen K, Jorgensen JOL, Petersen I, Sorensen HT. Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark. Eur J Endocrinol. 2019 181:267-273.
Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, Pacak K, Crona J, Zelinka T, Mannelli M, Deutschbein T, Timmers H, Castinetti F, Dralle H, Widimsky J, Gimenez-Roqueplo AP, Eisenhofer G. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hyp.ertension of the European Society of Hypertension. J Hypertens. 2020: 38:1443-1456.
Neumann HPH, Young WF, Jr., Eng C. Pheochromocytoma and Paraganglioma. The New England journal of medicine. 2019; 381:552-565.
Peitzsch M, Kaden D, Pamporaki C, Langton K, Constantinescu G, Conrad C, Fliedner S, Sinnott RO, Prejbisz A, Darr R, Lenders JWM, Bursztyn M, Eisenhofer G. Overnight/firstmorning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option? Eur J Endocrinol. 2020; 182:499-509.
Pernicova I, Kelly S, Ajodha S, Sahdev A, Bestwick JP, Gabrovska P, Akanle O, Ajjan R, Kola B, Stadler M, Fraser W, Christ-Crain M, Grossman AB, Pitzalis C, Korbonits M 2020 Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes Endocrinol. 2020 Apr; 8(4):278-291. https://doi.org/10.1016/S2213-8587(20)30021-8
Reimondo G, Castellano E, Grosso M, Priotto R, Puglisi S, Pia A, Pellegrino M, Borretta G, Terzolo M Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz284. https://doi.org/10.1210/clinem/dgz284
Rossi GP, Ceolotto G, Rossitto G, Maiolino G, Cesari M, Seccia TM. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism—the EMIRA Study. The Journal of Clinical Endocrinology & Metabolism. 2020; 105:2060-2067.
Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Schultzekool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Willenberg HS, Fuller P, Yang J, Nian Chee NY, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Chang CC, Wu VC, Somloova Z, Maiolino G, Barbiero G, Battistel M, Lenzini L, Quaia E, Pessina AC, Rossi GP 2020 Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. J Clin Endocrinol Metab. 2020 Jun 1;105(6):dgz017. https://doi.org/10.1210/clinem/dgz017
Sbardella E, Maunsell Z, May CJH, Tadman M, James T, Jafar-Mohammadi B, Isidori AM, Grossman AB, Shine B. Random 'spot' urinary metanephrines compared with 24-h-urinary and plasma results in phaeochromocytomas and paragangliomas. Eur J Endocrinol. 2020; 183:129-139.
Schimmack S, Kaiser J, Probst P, Kalkum E, Diener MK, Strobel O. Meta-analysis of alphablockade versus no blockade before adrenalectomy for phaeochromocytoma. Br J Surg. 2020 Jan;107(2):e102-e108. https://doi.org/10.1002/bjs.11348
Sherlock M, Scarsbrook A, Abbas A, Fraser S, Limumpornpetch P, Dineen R, Stewart PM Adrenal Incidentaloma. Endocr Rev. 2020 Dec 1;41(6):bnaa008. https://doi.org/10.1210/endrev/bnaa008
Wang K, Hu J, Yang J, Song Y, Fuller PJ, Hashimura H, He W, Feng Z, Cheng Q, Du Z, Wang Z, Ma L, Yang S, Li Q. Development and Validation of Criteria for Sparing Confirmatory Tests in Diagnosing Primary Aldosteronism. J Clin Endocrinol Metab. 2020 Jul 1;105(7):dgaa282. https://doi.org/10.1210/clinem/dgaa282
Zhang B, Ma S, Rachmin I, He M, Baral P, Choi S, Goncalves WA, Shwartz Y, Fast EM, Su Y, Zon LI, Regev A, Buenrostro JD, Cunha TM, Chiu IM, Fisher DE, Hsu YC. Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells. Nature. 2020; 577:676-681.

Alarkawi D, Ali MS, Bliuc D, Pallares N, Tebe C, Elhussein L, Caskey FJ, Arden NK, Ben- Shlomo Y, Abrahamsen B, Diez-Perez A, Pascual J, Pérez-Sáez MJ, Center JR, Judge A, Cooper C, Javaid MK, Prieto-Alhambra D. Oral bisphosphonate use and all‐cause mortality in patients with moderate–severe (Grade 3B‐5D) chronic kidney disease: A population‐based
Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2‐year clinical trial. J Bone Miner Res. 019;34:2220-2228.
Athimulam S, Delivanis D, Thomas M, Young WF, Khosla S, Drake MT, Bancos I. The impact of mild autonomous cortisol secretion on bone turnover markers. J Clin Endocrinol Metab. 2020; 105:1469-1477.
cohort study. Bone Miner Res. 2020;35:894-900.
https://doi.org/10.1210/clinem/dgaa174
Ejlsmark-Svensson H, Rolighed L, Rejnmark L. Effect of parathyroidectomy on cardiovascular risk factors in primary hyperparathyroidism: a randomized clinical trial. Ejlsmark-Svensson H et al., J Clin Endocrinol Metab. 2019;104(8):3223-3232.
Grey A, Horne A, Gamble G, Mihov B, Reid IR, Bolland M. Ten years of very infrequent zoledronate therapy in older women: an open-label extension of a randomized trial. J Clin Endocrinol Metab. 2020;105:1641-1647.
Halper-Stromberg E, Gallo T, Champakanath A, Taki I, Rewers M, Snell-Bergeon J, Frohnert BI, Shah VN. Bone mineral density across the lifespan in patients with type 1 diabetes. J Clin Endocrinol Metab. 2020;105:746-753.
Hiemstra TF, Lim K, Thadhani R, Manson JE. Vitamin D and atherosclerotic cardiovascular disease. J Clin Endocrinol Metab. 2019;104:4033-4050.
Hunt HB, Torres AM, Palomino PM, Marty E, Saiyed R, Cohn M, Jo J, Warner S, Sroga GE, King KB, Lane JM, Vashishth D, Hernandez CJ, Donnelly E. Altered tissue composition, microarchitecture, and mechanical performance in cancellous bone from men with type 2 diabetes mellitus. J Bone Miner Res. 2019;34:1191-1206. Oh TK & Song IA. Metformin therapy and hip fracture risk among patients with type II diabetes mellitus: A population-based cohort study. Bone. 2020;135: https://doi.org/10.1016/j.bone.2020.115325
Hygum K, Harsløf T, Jørgensen NR, Rungby J, Pedersen SB, Langdahl BL. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial. Bone. 2020;132: https://doi.org/10.1016/j.bone.2019.115197
Kim TY, Shoback DM, Black DM, Rogers SJ, Stewart L, Carter JT, Posselt AM, King NJ, Schafer AL. Increases in PYY and uncoupling of bone turnover are associated with loss of bone mass after gastric bypass surgery. Bone. 2020;131: https://doi.org/10.1016/j.bone.2019.115115
LeBoff MS, Chou SH, Murata EM, Donlon CM, Cook NR, Mora S, Lee IM, Kotler G, Bubes V, Buring JE, Manson JE. Effects of supplemental Vitamin D on bone health outcomes in women and men in the VITamin D and OmegA‐3 TriaL (VITAL). J Bone Miner Res. 2020;35:883-893
Leere JS, Karmisholt J, Robaczyk M, Lykkeboe S, Handberg A, Steinkohl E, Brøndum Frøkjær J, Vestergaard P. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabete Endocrinol. 2020;8(5):407-417.
Mannstadt M, Clarke BL, Bilezikian JP, Bone H, Denham D, Levine MA, Peacock M, Rothman J, Shoback DM, Warren ML, Watts NB, Lee HM, Sherry N, Vokes TJ. Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism. J Clin Endocrinol Metab. 2019;104:5136-514.
McKee H, Ioannidis G, Lau A, Treleaven D, Gangji A, Ribic C, Wong-Pack M, Papaioannou A, Adachi JD. Effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients. Osteoporos Int. 2020;35:516-527.
Palermo A, Naciu AM, Tabacco G, Falcone S, Santonati A, Maggi D, D'Onofrio L, Briganti SI, Castellitto D, Casini A, Pedone C, Lelli D, Fabbri A, Bilezikian JP, Napoli N, Pozzilli P, Manfrini S, Cesareo R. Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2020;105(7):
Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, Brodsky I, Ceglia L, Chadha C, Chatterjee R, Desouza C, Dolor R, Foreyt J, Fuss P, Ghazi A, Hsia DS, Johnson KC, Kashyap SR, Kim S, LeBlanc ES, Lewis MR, Liao E, Neff LM, Nelson J, O'Neil P, Park J, Peters A, Phillips LS, Pratley R, Raskin P, Rasouli N, Robbins D, Rosen C, Vickery EM, Staten M; D2d Research Group. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019;381:520-530.
Reid IR, Horne AM, Mihov B, Stewart A, Bastin S, Gamble GD. Zoledronate slows weight loss and maintains fat mass in osteopenic older women: secondary analysis of a randomized controlled trial. Calcif Tissue Int. 2020 Apr;106:386-391.
Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, Gamble GD. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res. 2020;35:20-27.
Shoback DL, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020;105:587–594.
Sølling AS, Harsløf T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: A randomized trial. J Bone Miner Res. 2020; https://doi.org/10.1002/jbmr.4098
Tsai JN, Lee H, David NL, Eastell R, Leder BZ. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): A randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019;7:767-775.
Yu EW, Tsourdi E, Clarke BL, Bauer DC, Drake MT. Osteoporosis management in the era of COVID‐19. J Bone Miner Res. 2020;35:1009-1013.
Zhang Y, Liu Z, Duan L, Ji Y, Yang S, Zhang Y, Li H, Wang Y, Wang P, Chen J, Li Y. Effect of low-dose vitamin K2 supplementation on bone mineral density in middle-aged and elderly Chinese: a randomized controlled study. Calcif Tissue Int. 2020;106(5):476-485.
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. (O’Neil et al., 2018, https://doi.org/10.1016/S0140-6736(18)31773-2)

Brandon P Galm, Nidan Qiao, Anne Klibanski, Beverly M K Biller, Nicholas A Tritos. Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome The Journal of Clinical Endocrinology & Metabolism, Volume 105, Issue 6, June 2020, Pages 2081- 2094, https://doi.org/10.1210/clinem/dgaa105.
Chiloiro S, Giampietro A, Frara S, Bima C, Donfrancesco F, Fleseriu CM, Pontecorvi A, Giustina A, Fleseriu M, De Marinis L, Bianchi A Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz054. https://doi.org/10.1210/clinem/dgz054
PMID: 31613969.
Coopmans EC, Berk KAC, El-Sayed N, Neggers SJCMM, van der Lely AJ.Eucaloric Very- Low-Carbohydrate Ketogenic Diet in Acromegaly Treatment.N Engl J Med. 2020 May 28;382(22):2161-2162. https://doi.org/10.1056/NEJMc1915808
Cristante J, Lefournier V, Sturm N, Passagia JG, Gauchez AS, Tahon F, Cantin S, Chabre O, Gay E. Why we should still treat by neurosurgery patients with Cushing's disease and a normal or inconclusive pituitary MRI. J Clin Endocrinol Metab. 2019 May 14:jc.2019-00333. https://doi.org/10.1210/jc.2019-00333 Epub ahead of print. PMID: 31087046.
Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z, Hadzalic A, Gorar S, Omma T, Mert M, Akbaba G, Yalin GY, Bayram F, Ozkan M, Yarman S.Dogansen SC, et al. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2527-2534. https://doi.org/10.1210/jc.2018-02202
Esposito D, Ragnarsson O, Johannsson G, Olsson DS.Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020 Jun;182(6):523-531. https://doi.org/10.1530/EJE-20-0019
PMID: 32213651
Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A. Advances in the medical treatment of Cushing's syndrome. Lancet Diabetes Endocrinol. 2019 Apr;7(4):300-312. https://doi.org/10.1016/S2213-8587(18)30155-4 Epub 2018 Jul 20. PMID: 30033041.
Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA, Geer EB, Greenman Y, Witek P, Cohen F, Biller BMK. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol. 2019 Sep 18. pii: S2213- 8587(19)30313-4. https://doi.org/10.1016/S2213-8587(19)30313-4
Ghajar A, Jones PS, Guarda FJ, Faje A, Tritos NA, Miller KK, Swearingen B, Nachtigall LB.Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time. J Clin Endocrinol Metab. 2020 Mar1;105(3):dgz187. https://doi.org/10.1210/clinem/dgz187
PMID: 31701145
Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S.A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz096. https://doi.org/10.1210/clinem/dgz096
Hannon AM, O'Shea T, Thompson CA, Hannon MJ, Dineen R, Khattak A, Gibney J, O'Halloran DJ, Hunter S, Thompson CJ, Sherlock M Pregnancy in acromegaly is safe and is associated with improvements in IGF-1 concentrations. .Eur J Endocrinol. 2019 Apr 1;180(4):K21-K29. https://doi.org/10.1530/EJE-18-0688
Kleindienst A, Georgiev S, Schlaffer SM, Buchfelder M. Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery. J Endocr Soc. 2020 Jun 9;4(7):bvaa068. https://doi.org/10.1210/jendso/bvaa068
eCollection 2020 Jul 1.
Knappe UJ, Petroff D, Quinkler M, Schmid SM, Schöfl C, Schopohl J, Stieg MR, Tönjes A; participants of the German Acromegaly Registry Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry. .Eur J Endocrinol. 2020 Mar;182(3):275-284. https://doi.org/10.1530/EJE-19-0784
PMID:31917680.
Mazziotti G, Battista C, Maffezzoni F, Chiloiro S, Ferrante E, Prencipe N, Grasso L, Gatto F, Olivetti R, Arosio M, Barale M, Bianchi A, Cellini M, Chiodini I, De Marinis L, Del Sindaco G, Di Somma C, Ferlin A, Ghigo E, Giampietro A, Grottoli S, Lavezzi E, Mantovani G, Morenghi E, Pivonello R, Porcelli T, Procopio M, Pugliese F, Scillitani A, Lania AG. Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study. J Clin Endocrinol Metab. 2020 Sep 1;105(9):dgaa363. https://doi.org/10.1210/clinem/dgaa363
PMID: 32511698
Melmed S.Pituitary-Tumor Endocrinopathies. N Engl J Med. 2020 Mar 5;382(10):937-950. https://doi.org/10.1056/NEJMra1810772
Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson ML, Septier A, Letourneur F, Diry S, Diedisheim M, Izac B, Gaspar C, Perlemoine K, Verjus V, Bernier M, Boulin A, Emile JF, Bertagna X, Jaffrezic F, Laloe D, Baussart B, Bertherat J, Gaillard S, Assié G.Neou M, et al. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell. 2020 Jan13;37(1):123-134.e5.
Newell-Price J, Nieman LK, Reincke M, Tabarin A.Newell-Price J, et al. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome. Eur J Endocrinol. 2020 Jul;183(1):G1-G7. https://doi.org/10.1530/EJE-20-0352
Papakokkinou E, Olsson DS, Chantzichristos D, Dahlqvist P, Segerstedt E, Olsson T, Petersson M, Berinder K, Bensing S, Höybye C, Edén-Engström B, Burman P, Bonelli L, Follin C, Petranek D, Erfurth EM, Wahlberg J, Ekman B, Åkerman AK, Schwarcz E, Bryngelsson IL, Johannsson G,Ragnarsson O.J Excess Morbidity Persists in Patients With Cushing's Disease During Long-term Remission: A Swedish Nationwide Study. Clin Endocrinol Metab. 2020 Aug 1;105(8):dgaa291. https://doi.org/10.1210/clinem/dgaa291
Parolin M, Dassie F, Alessio L, Wennberg A, Rossato M, Vettor R, Maffei P, Pagano C Obstructive Sleep Apnea in Acromegaly and the Effect of Treatment: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz116. https://doi.org/10.1210/clinem/dgz116
PMID: 31722411.
Quinkler M, Petroff D, Knappe UJ, Schopohl J, Tönjes A, Schmid SM Medical Therapy of Acromegaly in Germany 2019 - Data from the German Acromegaly Registry. .Exp Clin Endocrinol Diabetes. 2020 Jun 30. https://doi.org/10.1055/a-1191-2437
Ragnarsson O, Olsson DS, Chantzichristos D, Papakokkinou E, Dahlqvist P, Segerstedt E, Olsson T, Petersson M, Berinder K, Bensing S, Höybye C, Edén Engström B, Burman P, Bonelli L, Follin C, Petranek D, Erfurth EM, Wahlberg J, Ekman B, Åkerman AK, Schwarcz E, Bryngelsson IL, Johannsson G. The incidence of Cushing's disease: a nationwide Swedish study. Pituitary. 2019 Apr;22(2):179-186. https://doi.org/10.1007/s11102-019-00951-1
Ragnarsson O, Olsson DS, Papakokkinou E, Chantzichristos D, Dahlqvist P, Segerstedt E, Olsson T, Petersson M, Berinder K, Bensing S, Höybye C, Edén- Engström B, Burman P, Bonelli L, Follin C, Petranek D, Erfurth EM, Wahlberg J, EkmanB, Åkerman AK, Schwarcz E, Bryngelsson IL, Johannsson G. Overall and Disease- Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study. J Clin Endocrinol Metab. 2019 Jun 1;104(6):2375-2384. https://doi.org/10.1210/jc.2018-02524
Richter J, Herzog N, Janka S, Baumann T, Kistenmacher A, Oltmanns KM.Richter J, et al. Twice as High Diet-Induced Thermogenesis After Breakfast vs Dinner On High-Calorie as Well as Low-Calorie Meals. Among authors: herzog n. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz311. https://doi.org/10.1210/clinem/dgz311
Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, Zacharieva S, Machado MC, Hanzu FA, Zopp S, Ritzel K, Riester A, Braun LT, Kreitschmann-Andermahr I, Storr HL, Bansal P, Barahona MJ, Cosaro E, Dogansen SC, Johnston PC, Santos de Oliveira R, Raftopoulos C, Scaroni C, Valassi E, van der Werff SJA, Schopohl J, Beuschlein F, Reincke M. Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5367 Patients. JCEM 2020. https://doi.org/10.1210/clinem/dgz136
Stroud A, Dhaliwal P, Alvarado R, Winder MJ, Jonker BP, Grayson JW, Hamizan A, Harvey RJ, McCormack A. Outcomes of pituitary surgery for Cushing's disease: a systematic review and meta-analysis. Pituitary. 2020 Jul 20. https://doi.org/10.1007/s11102-020-01066-8
Online ahead of print.PMID: 32691356 Review.
Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C.Trouillas J, et al. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers (Basel). 2020 Feb 22;12(2):514.
Van't Westeinde A, Karlsson L, Nordenström A, Padilla N, Lajic S.Van't Westeinde A, et al. First-Trimester Prenatal Dexamethasone Treatment Is Associated With Alterations in Brain Structure at Adult Age. J Clin Endocrinol Metab. 2020 Aug 1;105(8):dgaa340. https://doi.org/10.1210/clinem/dgaa340
Villa C, Vasiljevic A, Jaffrain-Rea ML, Ansorge O, Asioli S, Barresi V, Chinezu L, Gardiman MP, Lania A, Lapshina AM, Poliani L, Reiniger L, Righi A, Saeger W, Soukup J, Theodoropoulou M, Uccella S, Trouillas J, Roncaroli F.Villa C, et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch. 2019 Dec;475(6):687-692. https://doi.org/10.1007/s00428-019-02655-0.
Epub 2019 Oct 2.Virchows Arch. 2019. PMID: 31578606 Review.
Wallensteen L, Karlsson L, Messina V, Nordenström A, Lajic S.Wallensteen L, et al. Perturbed Beta-Cell Function and Lipid Profile After Early Prenatal Dexamethasone Exposure in Individuals Without CAH. J Clin Endocrinol Metab. 2020 Jul 1;105(7):dgaa280. https://doi.org/10.1210/clinem/dgaa280
Wei R, Jiang C, Gao J, Xu P, Zhang D, Sun Z, Liu X, Deng K, Bao X, Sun G, Yao Y, Lu L, Zhu H, Wang R, Feng M.Wei R, et al. Deep-Learning Approach to Automatic Identification of Facial Anomalies in Endocrine Disorders. Neuroendocrinology. 2020;110(5):328-337. https://doi.org/10.1159/000502211
Yang C, Li G, Jiang S, Bao X, Wang R.Yang C, et al. Preoperative Somatostatin Analogues in Patients with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of Comparative Studies. Sci Rep. 2019 Oct 1;9(1):14070. https://doi.org/10.1038/s41598-019-50639-6.
Sci Rep. 2019. PMID: 31575930 Free PMC article.
Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akkervan Marle ME, Pereira AM, Peul WC, Dekkers OM, van Furth WR, Biermasz NR Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e32-41. https://doi.org/10.1210/clinem/dgz144

Ahn D, Lee GJ, Sohn JH. Levothyroxine Supplementation Following Hemithyroidectomy: Incidence, Risk Factors, and Characteristics. Ann Surg Oncol. 2019;26(13):4405-4413.
Bekkering GE, Agoritsas T, Lytvyn L, et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019;365:l2006 https://doi.org/10.1136/bmj.l2006
Biondi B, Cappola AR, Cooper DS. Subclinical Hypothyroidism: A Review. JAMA. 2019;322(2):153-160.
Cabanillas ME, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev. 2019 Dec 1;40(6):1573-1604.
Capdevila, J., Wirth, L.J., Ernst, T., Ponce Aix, S., Lin, C.-C., Ramlau, R., Butler, M.O., Delord, J.-P., Gelderblom, H., Ascierto, P.A., Fasolo, A., Führer, D., Hütter-Krönke, M.L., Forde, P.M., Wrona, A., Santoro, A., Sadow, P.M., Szpakowski, S., Wu, H., Bostel, G., Faris, J., Cameron, S., Varga, A., Taylor, M., 2020. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J. Clin. Oncol. JCO.19.02727.
Castellana M, Castellana C, Treglia G, Giorgino F, Giovanella L, Russ G, Trimboli, P. Performance of Five Ultrasound Risk Stratification Systems in Selecting Thyroid Nodules for FNA J Clin Endocrinol Metab 2020 May 1;105(5).
Ceolin L, Duval MADS, Benini AF, Ferreira CV, Maia AL. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr. Relat. Cancer 2019 Aug 1;26(9):R499-R518.
Derakhshan A, Peeters RP, Taylor PN, et al. Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis. Lancet Diabetes Endocrinol. 2020;8(6):501-510.
Dhillon-Smith RK, Middleton LJ, Sunner KK, et al. Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. N Engl J Med. 2019;380(14):1316- 1325.
Dias-Santagata D, Lennerz JK, Sadow PM, Frazier RP, Raju SG, Henry D, Chung T, Kherani J, Rothenberg SM, Wirth LJ. Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. Thyroid. 2020 May 19.
Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020;382(4):341-352.
Francis T, Francis N, Lazarus JH, Okosieme OE. Safety of antithyroid drugs in pregnancy: update and therapy implications. Expert Opin Drug Saf. 2020;19(5):565- 576.
Fugazzola, L., Elisei, R., Fuhrer, D., Jarzab, B., Leboulleux, S., Newbold, K., Smit, J., 2019. 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. Eur. Thyroid J. 8, 227–245.
Jabbar A, Ingoe L, Junejo S, et al. Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction. JAMA. 2020;324(3):249.
Jansen TA, Korevaar TIM, Mulder TA, et al. Maternal thyroid function during pregnancy and child brain morphology: a time window-specific analysis of a prospective cohort. lancet Diabetes Endocrinol. 2019;7(8):629-637.
Korevaar TIM, Derakhshan A, Taylor PN, et al. Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity with Preterm Birth: A Systematic Review and Meta-analysis. JAMA - J Am Med Assoc. 2019;322(7):632-641.
Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. Eur J Endocrinol. 2019;180(6):407-416.
Livhits MJ, Zhu CY, Kuo EJ, Nguyen DT, Kim J, Tseng CH, Leung AM, Rao J, Levin M, Douek ML, Beckett KR, Cheung DS, Gofnung YA, Smooke-Praw S, Yeh MW. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial. JAMA Oncol. 2020 Dec 10. https://doi.org/10.1001/jamaoncol.2020.5935
Luster M, Aktolun C, Amendoeira I, Barczyński M, Bible KC, Duntas LH, Elisei R, Handkiewicz-Junak D, Hoffmann M, Jarząb B, Leenhardt L, Musholt TJ, Newbold K, Nixon IJ, Smit J, Sobrinho-Simões M, Sosa JA, Tuttle RM, Verburg FA, Wartofsky L, Führer D. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid. 2019 Jan;29(1):7-26.
McLeod DS, Zhang L, Durante C, Cooper DS. Contemporary Debates in Adult Papillary Thyroid Cancer Management. Endocr Rev 2019 40(6):1481-1499.
Memeh K, Ruhle B, Vaghaiwalla T, Kaplan E, Keutgen X, Angelos P. Thyroidectomy for euthyroid patients with Hashimoto thyroiditis and persisting symptoms: A cost-effectiveness analysis. Surgery. 2020 May 24;S0039-6060(20)30172-0. https://doi.org/10.1016/j.surg.2020.03.028
Mirallié E, Borel F, Tresallet C, et al. Impact of total thyroidectomy on quality of life at 6 months: The prospective ThyrQoL multicentre trial. Eur J Endocrinol. 2020;182(2):195-205.
Mooijaart SP, Du Puy RS, Stott DJ, et al. Association Between Levothyroxine Treatment and Thyroid-Related Symptoms Among Adults Aged 80 Years and Older With Subclinical Hypothyroidism. JAMA. October 2019:1-11 https://doi.org/10.1001/jama.2019.17274
Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid. 2020 May 8. https://doi.org/10.1089/thy.2020.0032
Pang X, Pu T, Xu L, Sun R. Effect of l-thyroxine administration before breakfast vs at bedtime on hypothyroidism: A meta-analysis. Clin Endocrinol (Oxf). 2020;92(5) :475-481. https://doi.org/10.1111/cen.14172
Papoian V, Ylli D, Felger EA, Wartofsky L, Rosen JE. Evaluation of Thyroid Hormone Replacement Dosing in Overweight and Obese Patients after a Thyroidectomy. Thyroid. 2019;29(11):1558-1562.
Russell JO, Razavi CR, Shaear M, Chen LW, Lee AH, Ranganath R, Tufano RP. Transoral Vestibular Thyroidectomy: Current State of Affairs and Considerations for the Future. J Clin Endocrinol Metab. 2019 Mar 12. pii: jc.2019-00116
Thavaraputta S, Dennis JA, Laoveeravat P, Nugent K, Rivas AM. Hypothyroidism and Its Association With Sleep Apnea Among Adults in the United States: NHANES 2007-2008. J Clin Endocrinol Metab. 2019;104(11):4990-4997.
Tiedje, V., Fagin, J.A., 2020. Therapeutic breakthroughs for metastatic thyroid cancer. Nat. Rev. Endocrinol.
Tonacchera M, Chiovato L, Bartalena L, Cavaliere AF, Vitti P. Treatment of Graves’ hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy. J Endocrinol Invest. 2020;43(2):257-265.
Torlinska B, Nichols L, Mohammed MA, McCabe C, Boelaert K. Patients Treated for Hyperthyroidism Are at Increased Risk of Becoming Obese: Findings from a Large Prospective Secondary Care Cohort. Thyroid. 2019;29(10):1380-1389.
Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, Dillehay G, Draganescu C, Flux G, Führer D, Giovanella L, Greenspan B, Luster M, Muylle K, Smit JWA, Van Nostrand D, Verburg FA, Hegedüs L. Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019 Apr;29(4):461-470.
Wiersinga WM. T4 + T3 combination therapy: any progress? Endocrine. 2019;66(1):70- 78.
Wirth, L.J. et al. Efficacy of selpercatinib in RET-alteerd thyroid cancers. N Engl J Med 383:825-835, 2020.

Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei postmenopausalen Frauen und Männern (DVO, 2017, Retrieved from https://www.dv-osteologie.org/uploads/Leitlinie 2017/Finale Version Leitlinie Osteoporose 2017_end.pdf)
Geschlechtsinkongruenz, Geschlechtsdysphorie und Trans-Gesundheit: S3-Leitlinie zur Diagnostik, Beratung und Behandlung (AWMF, n.d., https://doi.org/10.2018/Version)
S2k-Leitlinie Neuroendokrine Tumore (Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) et al., 2018, https://doi.org/10.1055/a-0604-2924)
Nicht alkoholische Fettlebererkrankungen (Roeb et al., 2015, https://doi.org/10.1055/s-0035-1553193)
S1-Leitlinie Gynäkomastie im Erwachsenenalter (Schanz et al., n.d., Retrieved from https://www.awmf.org/uploads/tx_szleitlinien/013-039l_S1_Gynaekomastie_Erwachsene_2016-05.pdf)
Operative Therapie benigner Schilddrüsenerkrankungen (Retrieved from https://www.awmf.org/uploads/tx_szleitlinien/088-007l_S2k_operative_Therapie_benigner_Schilddrüsenerkrankungen_2015-10.pdf)
S2k-Leitlinie Operative Therapie von Nebennierentumoren (Retrieved from https://www.awmf.org/uploads/tx_szleitlinien/088-008l_S2k_Operative-Therapie_Nebennierentumoren_2018-11.pdf)
Erhöhter TSH-Wert in der Hausarztpraxis (Retrieved from https://www.awmf.org/uploads/tx_szleitlinien/053-046l_S2k_erhoehter_TSH_Wert_2017-04.pdf)
S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ) (Schiegnitz et al., n.d., Retrieved from https://www.awmf.org/uploads/tx_szleitlinien/007-091l_S3_Antiresorptiva-assoziierte-Kiefernekrosen-AR-ONJ_2018-12.pdf)

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Davies et al., 2018, https://doi.org/10.2337/dci18-0033)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.(Grundy et al., 2018, https://doi.org/10.1161/CIR.0000000000000625)
Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome (Teede et al., 2018, https://doi.org/10.1093/humrep/dey256)
ESHRE Guideline: management of women with premature ovarian insufficiency.(European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI et al., 2016, https://doi.org/10.1093/humrep/dew027)
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. (Fassnacht et al., 2016, https://doi.org/10.1530/EJE-16-0467)
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors(Fassnacht et al., 2018, https://doi.org/10.1530/EJE-18-0608)
European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma (Plouin et al., 2016, https://doi.org/10.1530/EJE-16-0033)
Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency.(Husebye et al., 2014, https://doi.org/10.1111/joim.12162)
European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma (Gaujoux & Mihai, 2017, https://doi.org/10.1002/bjs.10414)
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas (Raverot et al., 2018, https://doi.org/10.1530/EJE-17-0796)
Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting.(Gravholt et al., 2017, https://doi.org/10.1530/EJE-17-0430)
European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults.(Bollerslev et al., 2015, https://doi.org/10.1530/EJE-15-0628)
Clinical practice guideline on diagnosis and treatment of hyponatraemia (Spasovski et al., 2014, https://doi.org/10.1530/EJE-13-1020)

https://www.eurothyroid.com/guidelines/eta_guidelines.html
2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism.(Persani et al., 2018, https://doi.org/10.1159/000491388)
2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.(Kahaly et al., 2018, https://doi.org/10.1159/000490384)
2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.(Bartalena et al., 2018, https://doi.org/10.1159/000486957)
European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS.(Russ et al., 2017, https://doi.org/10.1159/000478927)
The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (Biondi et al., 2015, https://doi.org/10.1159/000438750)
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.(Bartalena et al., 2016, https://doi.org/10.1159/000443828)
2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer.(Leenhardt et al., 2013, https://doi.org/10.1159/000354537)

https://www.thyroid.org/professionals/ata-professional-guidelines
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer (Haugen et al., 2015, https://doi.org/10.1089/thy.2015.0020)
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum (Alexander et al., 2017, https://doi.org/10.1089/thy.2016.0457)
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (Ross et al., 2016, https://doi.org/10.1089/thy.2016.0229)
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (Wells et al., 2015, https://doi.org/10.1089/thy.2014.0335)
Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (Jonklaas et al., 2014, https://doi.org/10.1089/thy.2014.0028)
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer (Smallridge et al., 2012, https://doi.org/10.1089/thy.2012.0302)

https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines

Adrenal

Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency | 2018: https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/primary-aldosteronism
The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment | 2016: https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/primary-aldosteronism
Diagnosis and Treatment of Primary Adrenal Insufficiency | 2016: https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/primary-adrenal-insufficiency
Treatment of Cushing’s Syndrome | 2015: https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/treatment-of-cushing-syndrome
Diagnosis and Treatment of Pheochromocytoma and Paraganglioma | 2014 https://doi.org/10.1210/jc.2014-1498
Diagnosis of Cushing's Syndrome | 2008 https://doi.org/10.1210/jc.2008-0125

Bone Health and Osteoporosis

Paget's Disease of Bone | 2014 https://doi.org/10.1210/jc.2014-2910
Osteoporosis in Men | 2012 https://doi.org/10.1210/jc.2011-3045
Evaluation, Treatment, and Prevention of Vitamin D Deficiency | 2011 https://doi.org/10.1210/jc.2011-0385

Cardiovascular Endocrinology

The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment | 2016 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/primary-aldosteronism
Evaluation and Treatment of Hypertriglyceridemia | 2012 https://doi.org/10.1210/jc.2011-3213

Glucose Metabolism

Evaluation and Management of Adult Hypoglycemic Disorders | 2009 https://doi.org/10.1210/jc.2008-1410

Endocrine Neoplasia and Cancer

Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer | 2018 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/disorders-in-survivors-of-childhood-cancer

Female Reproductive Endocrinology

Evaluation and Treatment of Hirsutism in Premenopausal Women | 2018 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/hirsutism
Functional Hypothalamic Amenorrhea | 2017 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/hypothalamic-amenorrhea
Treatment of Symptoms of the Menopause | 2015 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/treatment-of-menopause

Male Reproductive Endocrinology

Testosterone Therapy in Men with Hypogonadism ǀ 2018 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/testosterone-therapy

Neuroendocrinology

Hormonal Replacement in Hypopituitarism in Adults | 2016 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/hormone-replacement-in-hypopituitarism
Acromegaly | 2014 https://doi.org/10.1210/jc.2014-2700
Diagnosis and Treatment of Hyperprolactinemia | 2011 https://doi.org/10.1210/jc.2010-1692
Evaluation and Treatment of Adult Growth Hormone Deficiency | 2011 https://doi.org/10.1210/jc.2011-0179
Pituitary Incidentaloma | 2011 https://doi.org/10.1210/jc.2010-1048

Transgender Medicine

Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons | 2017 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/gender-dysphoria-gender-incongruence